EA009369B1 - Производные гидроксизамещенного 1,3,8-триазинспиро[4,5]декан-4-она, полезные для лечения расстройств, опосредованных orl-рецептором - Google Patents

Производные гидроксизамещенного 1,3,8-триазинспиро[4,5]декан-4-она, полезные для лечения расстройств, опосредованных orl-рецептором Download PDF

Info

Publication number
EA009369B1
EA009369B1 EA200500331A EA200500331A EA009369B1 EA 009369 B1 EA009369 B1 EA 009369B1 EA 200500331 A EA200500331 A EA 200500331A EA 200500331 A EA200500331 A EA 200500331A EA 009369 B1 EA009369 B1 EA 009369B1
Authority
EA
Eurasian Patent Office
Prior art keywords
alkyl
group
ethyl
hydroxy
propyl
Prior art date
Application number
EA200500331A
Other languages
English (en)
Russian (ru)
Other versions
EA200500331A1 (ru
Inventor
Кэтлин Баттиста
Жилль Биньян
Питер Дж. Коннолли
Аллен Б. Рейтц
Тина Морган Росс
Малколм Скотт
Стивен А. Миддлтон
Майкл Орсини
Original Assignee
Янссен Фармацевтика, Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31978719&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA009369(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Янссен Фармацевтика, Н.В. filed Critical Янссен Фармацевтика, Н.В.
Publication of EA200500331A1 publication Critical patent/EA200500331A1/ru
Publication of EA009369B1 publication Critical patent/EA009369B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EA200500331A 2002-09-09 2003-09-05 Производные гидроксизамещенного 1,3,8-триазинспиро[4,5]декан-4-она, полезные для лечения расстройств, опосредованных orl-рецептором EA009369B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40913402P 2002-09-09 2002-09-09
PCT/US2003/027956 WO2004022558A2 (en) 2002-09-09 2003-09-05 Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders

Publications (2)

Publication Number Publication Date
EA200500331A1 EA200500331A1 (ru) 2005-08-25
EA009369B1 true EA009369B1 (ru) 2007-12-28

Family

ID=31978719

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500331A EA009369B1 (ru) 2002-09-09 2003-09-05 Производные гидроксизамещенного 1,3,8-триазинспиро[4,5]декан-4-она, полезные для лечения расстройств, опосредованных orl-рецептором

Country Status (19)

Country Link
US (3) US7081463B2 (enExample)
EP (1) EP1601674B1 (enExample)
JP (1) JP4712384B2 (enExample)
KR (1) KR20050043935A (enExample)
CN (1) CN100402529C (enExample)
AR (1) AR041205A1 (enExample)
AU (1) AU2003268512A1 (enExample)
BR (1) BR0306309A (enExample)
CA (1) CA2498275C (enExample)
CL (1) CL2003001814A1 (enExample)
EA (1) EA009369B1 (enExample)
MX (1) MXPA05002622A (enExample)
NO (1) NO20051743L (enExample)
NZ (1) NZ538307A (enExample)
PL (1) PL377047A1 (enExample)
RS (1) RS20050208A (enExample)
TW (1) TWI296627B (enExample)
WO (1) WO2004022558A2 (enExample)
ZA (1) ZA200502836B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050043935A (ko) * 2002-09-09 2005-05-11 얀센 파마슈티카 엔.브이. Orl-1 수용체 매개 장애의 치료에 유용한 하이드록시 알킬 치환된 1,3,8-트리아자스피로[4.5]데칸-4-온 유도체
NZ544282A (en) * 2003-05-23 2009-07-31 Zealand Pharma As Triaza-spiro compounds as nociceptin analogues and uses thereof
AR046756A1 (es) 2003-12-12 2005-12-21 Solvay Pharm Gmbh Derivados de hidronopol como agonistas de receptores orl-1 humanos.
US20060178390A1 (en) * 2004-08-02 2006-08-10 Alfonzo Jordan 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
BRPI0616618A2 (pt) * 2005-09-28 2011-06-28 Hoffmann La Roche derivados de indol-3-il-carbonil-azaespiro como antagonistas de receptor de vasopressina
TW200819457A (en) 2006-08-30 2008-05-01 Actelion Pharmaceuticals Ltd Spiro antibiotic derivatives
KR20090083954A (ko) * 2006-11-28 2009-08-04 얀센 파마슈티카 엔.브이. 3-(3-아미노-2-(r)-하이드록시프로필)-1-(4-플루오로페닐)-8-(8-메틸나프탈렌-1-일메틸)-1,3,8-트리아자-스피로[4.5]데칸-4-온의 염
KR20090087042A (ko) * 2006-11-28 2009-08-14 얀센 파마슈티카 엔.브이. 알콜 남용, 중독 및 의존증 치료방법
CA2683598C (en) * 2007-04-09 2015-11-17 Janssen Pharmaceutica Nv 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression
US20100076003A1 (en) * 2008-09-19 2010-03-25 Kathleen Battista 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators
UA107943C2 (xx) * 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
WO2014100719A2 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9611257B2 (en) 2012-12-21 2017-04-04 Epizyme, Inc. PRMT5 inhibitors and uses thereof
EP2935240A1 (en) 2012-12-21 2015-10-28 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2014100734A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US8940726B2 (en) 2012-12-21 2015-01-27 Epizyme, Inc. PRMT5 inhibitors and uses thereof
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環(4.5)癸烷衍生物
CA2953572A1 (en) 2014-08-04 2016-02-11 Epizyme, Inc. Prmt5 inhibitors and uses thereof
KR102043337B1 (ko) 2014-08-28 2019-11-11 아셰뉴론 에스아 글리코시다제 저해제
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
EP3383390A4 (en) * 2015-12-02 2019-11-20 Astraea Therapeutics, LLC PIPERIDINYL-nociceptin RECEPTOR COMPOUNDS
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
MA43677A (fr) 2016-02-25 2018-11-28 Asceneuron Sa Inhibiteurs de glycosidases
MA43680A (fr) 2016-02-25 2018-11-28 Asceneuron Sa Inhibiteurs de glycosidases
KR102800480B1 (ko) 2016-02-25 2025-04-25 아셰뉴론 에스아 피페라진 유도체의 산 부가 염
EP3672959A1 (en) 2017-08-24 2020-07-01 Asceneuron SA Linear glycosidase inhibitors
HUE067314T2 (hu) 2017-09-22 2024-10-28 Jubilant Epipad LLC Heterociklusos vegyületek mint PAD gátlók
KR102782563B1 (ko) 2017-10-18 2025-03-14 주빌런트 에피파드 엘엘씨 Pad 억제제로서의 이미다조-피리딘 화합물
KR20200085836A (ko) 2017-11-06 2020-07-15 주빌런트 프로델 엘엘씨 Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
BR112020010322A2 (pt) 2017-11-24 2020-11-17 Jubilant Episcribe Llc composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer
SG11202008950PA (en) 2018-03-13 2020-10-29 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors
SG11202101651RA (en) 2018-08-22 2021-03-30 Asceneuron S A Succinate and fumarate acid addition salts of piperazine derivatives useful as glycosidase inhibitors
WO2020039029A1 (en) * 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329353A (en) * 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
EP0856514A1 (en) * 1997-01-30 1998-08-05 F. Hoffmann-La Roche Ag 8-substituted-1,3,8-triazaspiro[4.5]decan-4-on derivatives
EP0921125A1 (en) * 1997-12-05 1999-06-09 F. Hoffmann-La Roche Ag 1,3,8-Triaza-spiro 4,5 decan-4-on derivatives
WO1999059997A1 (en) * 1998-05-18 1999-11-25 Novo Nordisk A/S Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
WO2000006545A1 (en) * 1998-07-27 2000-02-10 Schering Corporation High affinity ligands for nociceptin receptor orl-1
EP0997464A1 (en) * 1998-10-23 2000-05-03 Pfizer Inc. 1,3,8-Triazaspiro[4,5] decanone compounds as orl1-receptor agonists
WO2001007050A1 (en) * 1999-07-26 2001-02-01 Schering Corporation Nociceptin receptor orl-1 agonists for use in treating cough
WO2001036418A1 (en) * 1999-11-17 2001-05-25 Novo Nordisk A/S Novel triazaspirodecanones with high affinity for opioid receptor subtypes
WO2001039723A2 (en) * 1999-12-06 2001-06-07 Euro-Celtique, S.A. Triazospiro compounds having nociceptin receptor affinity
WO2001046192A1 (en) * 1999-12-22 2001-06-28 Meiji Seika Kaisha, Ltd. SPIRO COMPOUNDS USEFUL AS OPIOID δ RECEPTOR AGONIST
WO2001094346A1 (en) * 2000-06-08 2001-12-13 F. Hoffmann-La Roche Ag 1,3,8-TRIAZA-SPIRO'4,5!DECAN-4-ONE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS
WO2002083673A1 (en) * 2001-04-10 2002-10-24 Ortho-Mcneil Pharmaceutical, Inc. 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US677421A (en) * 1900-10-19 1901-07-02 Kate Hatch Mcrae Cake-beater.
US3155699A (en) 1960-03-30 1964-11-03 Mobay Chemical Corp Purification of isocyanates by reduction of the hydrolyzable chlorine and acid content
US3155670A (en) 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes
US3161644A (en) 1962-06-22 1964-12-15 Res Lab Dr C Janssen N V 1-benzyl-4-substituted piperidines
US3238216A (en) 1963-06-20 1966-03-01 Res Lab Dr C Janssen N V Substituted 1, 3, 8-triaza-spiro (4, 5) decanes
US3839340A (en) * 1968-09-27 1974-10-01 Fmc Corp Substituted 1,3,8-triazaspiro{8 4.5{9 decanes
US3629267A (en) 1968-10-28 1971-12-21 Smith Kline French Lab Benzoheterocyclicalkyl derivatives of 4-(2-keto -1-benzimidazolinyl)-piperidine 4-(2-keto - 1 - benzimidazolinyl) -1 2 3 6 tetrahydropyridine 1 - phenyl - 1 3 8-triazaspiro(4 5)decan - 4 - one and 2 4 9-triazaspiro(5 5)undecan-1 3 5-trione
US3859340A (en) 1970-09-09 1975-01-07 Squibb & Sons Inc ' -methylfluorene-2-acetic acid
US4020072A (en) 1976-05-04 1977-04-26 E. R. Squibb & Sons, Inc. 5-Aminomethyl-1H-pyrazolo[3,4-b]pyridines
JPS54109983A (en) 1978-02-13 1979-08-29 Sumitomo Chem Co Ltd Novel spiroamine derivative and its preparation
US4329363A (en) 1978-09-08 1982-05-11 Merck & Co., Inc. Substituted mercapto acid amides and their use
US4526896A (en) 1978-12-26 1985-07-02 Riker Laboratories, Inc. Tetrazol-5-yl 2-nitro-3-phenylbenzofurans and antimicrobial use thereof
JPS57212180A (en) 1981-06-19 1982-12-27 Yoshitomi Pharmaceut Ind Ltd Tetrahydrofuran(thiophene) compound
WO1988000190A1 (en) 1986-06-25 1988-01-14 Massachusetts Institute Of Technology Optically active derivatives of glycidol
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
DE4135473A1 (de) 1991-10-28 1993-04-29 Bayer Ag Triazaspirodecanon-methylchromane
WO1993012789A1 (en) 1991-12-27 1993-07-08 Beth Israel Hospital Use of spiperone or spiperone derivatives as immunosuppressant agents
FR2708606B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
WO1995007294A1 (en) 1993-09-09 1995-03-16 Scios Nova Inc. Pseudo- and non-peptide bradykinin receptor antagonists
US5739336A (en) 1995-06-23 1998-04-14 Syntex (U.S.A.) Inc. 1,3,8-triaza- and 3,8-diaza-1-oxaspiro 4,5! decane derivatives
US5821219A (en) 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
EP0891332B1 (en) 1996-03-29 2004-03-17 Pfizer Inc. 6-phenylpyridyl-2-amine derivatives
US6013652A (en) 1997-12-04 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin antagonists
DE69803653T2 (de) * 1997-12-05 2002-08-29 F. Hoffmann-La Roche Ag, Basel 1,3,8-Triazaspiro[4,5]decan-4-on-derivate
US6277991B1 (en) * 1998-05-18 2001-08-21 Novo Nordisk A/S 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
SI0970957T1 (enExample) 1998-06-12 2001-12-31 Hoffmann La Roche
WO1999065494A1 (en) 1998-06-15 1999-12-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
AR021355A1 (es) 1998-11-20 2002-07-17 Smithkline Beecham Spa Derivados de quinolina. procedimiento para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de unmedicamento
JP2000169476A (ja) 1998-12-09 2000-06-20 Banyu Pharmaceut Co Ltd 4−オキソイミダゾリジン−5−スピロ−含窒素複素環式化合物
DE19956598A1 (de) 1999-11-25 2001-06-13 Bosch Gmbh Robert Ventil zum Steuern von Flüssigkeiten
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
WO2001096337A1 (en) 2000-06-14 2001-12-20 Banyu Pharmaceutical Co.,Ltd 4-oxoimidazolidine-2-spiro-nitrogenous heterocycle compounds
NZ528978A (en) 2001-04-18 2004-06-25 Euro Celtique S Spiropyrazole compounds
US20030078278A1 (en) 2001-06-26 2003-04-24 Pfizer Inc. Spiropiperidine compounds as ligands for ORL-1 receptor
ATE396995T1 (de) 2001-07-23 2008-06-15 Banyu Pharma Co Ltd 4-oxoimidazolidin-2-spiro piperidin derivat
US20040014955A1 (en) 2001-12-17 2004-01-22 Carlos Zamudio Identification of essential genes of cryptococcus neoformans and methods of use
JP2005519921A (ja) 2002-01-28 2005-07-07 ファイザー株式会社 Orl−1受容体リガンドとしてのn置換スピロピペリジン化合物
US20060058553A1 (en) 2002-02-07 2006-03-16 Axys Pharmaceuticals, Inc. Novel bicyclic hydroxamates as inhibitors of histone deacetylase
KR20050043935A (ko) * 2002-09-09 2005-05-11 얀센 파마슈티카 엔.브이. Orl-1 수용체 매개 장애의 치료에 유용한 하이드록시 알킬 치환된 1,3,8-트리아자스피로[4.5]데칸-4-온 유도체
WO2005016913A1 (en) 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
CA2546147A1 (en) 2003-12-23 2005-07-14 Arena Pharmaceuticals, Inc. Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
MX2007002033A (es) 2004-08-19 2007-04-26 Vertex Pharma Moduladores de receptores muscarinicos.
WO2006034110A1 (en) 2004-09-17 2006-03-30 Osi Pharmaceuticals, Inc. (arylamidoaryl) cyanoguanidine compounds as inhibitors of c-kit proto-oncogene
JP2008542375A (ja) 2005-06-02 2008-11-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Orl−1受容体モジュレーターとして有用な新規3−スピロ環式インドリル誘導体
KR20090087042A (ko) 2006-11-28 2009-08-14 얀센 파마슈티카 엔.브이. 알콜 남용, 중독 및 의존증 치료방법
CA2683598C (en) 2007-04-09 2015-11-17 Janssen Pharmaceutica Nv 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression
US20100076003A1 (en) 2008-09-19 2010-03-25 Kathleen Battista 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329353A (en) * 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
EP0856514A1 (en) * 1997-01-30 1998-08-05 F. Hoffmann-La Roche Ag 8-substituted-1,3,8-triazaspiro[4.5]decan-4-on derivatives
EP0921125A1 (en) * 1997-12-05 1999-06-09 F. Hoffmann-La Roche Ag 1,3,8-Triaza-spiro 4,5 decan-4-on derivatives
WO1999059997A1 (en) * 1998-05-18 1999-11-25 Novo Nordisk A/S Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
WO2000006545A1 (en) * 1998-07-27 2000-02-10 Schering Corporation High affinity ligands for nociceptin receptor orl-1
EP0997464A1 (en) * 1998-10-23 2000-05-03 Pfizer Inc. 1,3,8-Triazaspiro[4,5] decanone compounds as orl1-receptor agonists
WO2001007050A1 (en) * 1999-07-26 2001-02-01 Schering Corporation Nociceptin receptor orl-1 agonists for use in treating cough
WO2001036418A1 (en) * 1999-11-17 2001-05-25 Novo Nordisk A/S Novel triazaspirodecanones with high affinity for opioid receptor subtypes
WO2001039723A2 (en) * 1999-12-06 2001-06-07 Euro-Celtique, S.A. Triazospiro compounds having nociceptin receptor affinity
WO2001046192A1 (en) * 1999-12-22 2001-06-28 Meiji Seika Kaisha, Ltd. SPIRO COMPOUNDS USEFUL AS OPIOID δ RECEPTOR AGONIST
WO2001094346A1 (en) * 2000-06-08 2001-12-13 F. Hoffmann-La Roche Ag 1,3,8-TRIAZA-SPIRO'4,5!DECAN-4-ONE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS
WO2002083673A1 (en) * 2001-04-10 2002-10-24 Ortho-Mcneil Pharmaceutical, Inc. 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch, Week 200153 Derwent Publications Ltd., London, GB; Class B02, AN 2001-488618, XP002269085 -& WO 0146192 A (MEIJI SEIKA KAISHA LTD), 28 June 2001 (2001-06-28), abstract *

Also Published As

Publication number Publication date
EP1601674A2 (en) 2005-12-07
TWI296627B (en) 2008-05-11
WO2004022558A2 (en) 2004-03-18
WO2004022558A3 (en) 2004-05-21
PL377047A1 (pl) 2006-01-23
JP2006500393A (ja) 2006-01-05
AR041205A1 (es) 2005-05-11
KR20050043935A (ko) 2005-05-11
US20040142955A1 (en) 2004-07-22
ZA200502836B (en) 2006-06-28
CL2003001814A1 (es) 2005-02-11
EP1601674B1 (en) 2012-08-08
US20060030577A1 (en) 2006-02-09
RS20050208A (sr) 2007-08-03
NZ538307A (en) 2008-04-30
US20090124614A1 (en) 2009-05-14
US7081463B2 (en) 2006-07-25
CN100402529C (zh) 2008-07-16
CA2498275A1 (en) 2004-03-18
BR0306309A (pt) 2004-10-19
CA2498275C (en) 2011-07-12
US7582649B2 (en) 2009-09-01
JP4712384B2 (ja) 2011-06-29
US8778956B2 (en) 2014-07-15
NO20051743L (no) 2005-05-18
TW200418857A (en) 2004-10-01
CN1694883A (zh) 2005-11-09
MXPA05002622A (es) 2005-09-08
EA200500331A1 (ru) 2005-08-25
AU2003268512A1 (en) 2004-03-29

Similar Documents

Publication Publication Date Title
EA009369B1 (ru) Производные гидроксизамещенного 1,3,8-триазинспиро[4,5]декан-4-она, полезные для лечения расстройств, опосредованных orl-рецептором
EP1399445A2 (en) Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists
AU2002246726A1 (en) Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists
EP2767531B1 (en) Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same
AU5737900A (en) Substituted heterocycle fused gamma-carbolines
JP6173431B2 (ja) モルヒナン誘導体
EP1535922A1 (en) Pyrrolopyridine derivative and use thereof
EP0303387A1 (en) Kynurenic acid derivatives useful in the treatment of neurodegenerative disorders
TW201904946A (zh) 苯并氮呯衍生物
US4971966A (en) Substituted pyrido(2,3-B) (1,4) benzodiazepin-6-ones, and medicaments containing these compounds
US5175158A (en) Condensed diazepinones, processes for preparing them and pharmaceutical compositions containing these compounds
CN102159575A (zh) 可用作orl-1受体调节剂的5-唑烷-2-酮取代的1,3,8-三氮杂螺[4,5]癸-4-酮衍生物
JP2022509434A (ja) 疼痛に対して活性があるピペラジニル及びピペリジニルキナゾリン-4(3h)-オン誘導体
US4931436A (en) Condensed diazepinones, processes for preparing them and pharmaceutical compositions containing these compounds
EP0401779B1 (en) 4,5,5a,6-Tetrahydro-3H-isoxazolo (5,4,3-kl)acridines derivatives, a process for their preparation and their use as medicaments
JP3523887B2 (ja) 縮合複素環ケトン誘導体、その製造法、中間体および剤

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU